| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 630,200 | 838,000 | 426,410 | 356,130 | 227,980 |
| Sales Growth | -24.80% | +96.52% | +19.73% | +56.21% | +11.27% |
| Net Income | 37,730 | 100,780 | -360,840 | -194,650 | -125,730 |
| Net Income Growth | -62.56% | +127.93% | -85.38% | -54.82% | -18.59% |
Hutchmed China Ltd ADR (HCM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
HUTCHMED Limited is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. HUTCHMED Limited, formerly known as HUTCHMED (China) Limited, is based in HONG KONG.
Fiscal Year End Date: 12/31